392 related articles for article (PubMed ID: 10698472)
21. Lung cancer: chemoprevention and intermediate effect markers.
Tockman MS
IARC Sci Publ; 2001; 154():257-70. PubMed ID: 11220665
[TBL] [Abstract][Full Text] [Related]
22. Properties of intraepithelial neoplasia relevant to the development of cancer chemopreventive agents.
Boone CW; Bacus JW; Bacus JV; Steele VE; Kelloff GJ
J Cell Biochem Suppl; 1997; 28-29():1-20. PubMed ID: 9589346
[TBL] [Abstract][Full Text] [Related]
23. Cancer chemoprevention.
Hong WK; Lippman SM
J Natl Cancer Inst Monogr; 1995; (17):49-53. PubMed ID: 8573453
[TBL] [Abstract][Full Text] [Related]
24. Progress and perspectives in chemoprevention of head and neck cancer.
Wirth LJ; Haddad RI; Posner MR
Expert Rev Anticancer Ther; 2003 Jun; 3(3):339-55. PubMed ID: 12820777
[TBL] [Abstract][Full Text] [Related]
25. Biological relevance of adduct detection to the chemoprevention of cancer.
Sharma RA; Farmer PB
Clin Cancer Res; 2004 Aug; 10(15):4901-12. PubMed ID: 15297390
[TBL] [Abstract][Full Text] [Related]
26. Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice.
Gupta S; Ahmad N; Marengo SR; MacLennan GT; Greenberg NM; Mukhtar H
Cancer Res; 2000 Sep; 60(18):5125-33. PubMed ID: 11016639
[TBL] [Abstract][Full Text] [Related]
27. Mechanistic considerations in the evaluation of chemopreventive data.
Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet RA; Greenwald P; Hawk ET; Fay JR; Sigman CC
IARC Sci Publ; 1996; (139):203-19. PubMed ID: 8923032
[TBL] [Abstract][Full Text] [Related]
28. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
29. A clinical development paradigm for cancer vaccines and related biologics.
Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
[TBL] [Abstract][Full Text] [Related]
30. Cancer chemopreventive agents-drugs for the 21st century?
Baer-Dubowska W
Acta Pol Pharm; 2006; 63(5):369-73. PubMed ID: 17357586
[TBL] [Abstract][Full Text] [Related]
31. Endpoint markers for clinical trials of chemopreventive agents derived from the properties of epithelial precancer (intraepithelial neoplasia) measured by computer-assisted image analysis.
Boone CW; Kelloff GJ
Cancer Surv; 1998; 32():133-47. PubMed ID: 10489626
[TBL] [Abstract][Full Text] [Related]
32. G-actin as a risk factor and modulatable endpoint for cancer chemoprevention trials.
Hemstreet GP; Rao J; Hurst RE; Bonner RB; Waliszewski P; Grossman HB; Liebert M; Bane BL
J Cell Biochem Suppl; 1996; 25():197-204. PubMed ID: 9027619
[TBL] [Abstract][Full Text] [Related]
33. Modulation of biologic endpoints by topical difluoromethylornithine (DFMO), in subjects at high-risk for nonmelanoma skin cancer.
Einspahr JG; Nelson MA; Saboda K; Warneke J; Bowden GT; Alberts DS
Clin Cancer Res; 2002 Jan; 8(1):149-55. PubMed ID: 11801552
[TBL] [Abstract][Full Text] [Related]
34. Protocol design considerations that relate to demonstrating the safety and effectiveness of chemopreventive agents.
Johnson KA; Beitz J; Justice R; Schmidt W; Andrews P; DeLap R
J Cell Biochem Suppl; 1997; 27():1-6. PubMed ID: 9591186
[TBL] [Abstract][Full Text] [Related]
35. Summary of recommendations for colonic biomarker studies of candidate chemopreventive compounds in phase II clinical trials.
Lipkin M
J Cell Biochem Suppl; 1994; 19():94-8. PubMed ID: 7823612
[TBL] [Abstract][Full Text] [Related]
36. Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers.
Kelloff GJ; O'Shaughnessy JA; Gordon GB; Hawk ET; Sigman CC
Cancer Epidemiol Biomarkers Prev; 2003 Jul; 12(7):593-6. PubMed ID: 12869396
[No Abstract] [Full Text] [Related]
37. Clinical development of leukocyte cyclooxygenase 2 activity as a systemic biomarker for cancer chemopreventive agents.
Plummer SM; Hill KA; Festing MF; Steward WP; Gescher AJ; Sharma RA
Cancer Epidemiol Biomarkers Prev; 2001 Dec; 10(12):1295-9. PubMed ID: 11751448
[TBL] [Abstract][Full Text] [Related]
38. Micronutrients as chemopreventive agents.
Reddy BS
IARC Sci Publ; 1996; (139):221-35. PubMed ID: 8923033
[TBL] [Abstract][Full Text] [Related]
39. Clinical trials with retinoids for breast cancer chemoprevention.
Zanardi S; Serrano D; Argusti A; Barile M; Puntoni M; Decensi A
Endocr Relat Cancer; 2006 Mar; 13(1):51-68. PubMed ID: 16601279
[TBL] [Abstract][Full Text] [Related]
40. Breast cancer chemoprevention trials using the fine-needle aspiration model.
Kimler BF; Fabian CJ; Wallace DD
J Cell Biochem Suppl; 2000; 34():7-12. PubMed ID: 10762008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
